Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 1, 2011, Pages 9-37

  Zhang, Jian Ping ^a   Malhotra, Anil K ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotics; Clinical response; Pharmacogenetics; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BROMPERIDOL; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; EMONAPRIDE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SULPRIDE; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIOINFORMATICS; BODY WEIGHT; BRAIN; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITION; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS (TOPIC); METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; DOPAMINE; HUMANS; INDIVIDUALIZED MEDICINE; MOVEMENT DISORDERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEROTONIN;

EID: 78650472775     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.532787     Document Type: Review

References (204)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690):635-45
2. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
3. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
4. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1081-90
5. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic rugs. Mol Psychiatry 2005;10(1):79-104
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 2005;353(12):1209-23
7. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
8. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007;12(8):707-47
9. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. Am J Psychiatry 1981;138(4):460-4
10. Malhotra AK, Buchanan RW, Kim S. Allelic variation in the promotor region of the dopamine D2 receptor gene and clozapine response. Schizophr Res 1999;36:92-3
11. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006;163(3):529-31
12. Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci lett 2005;376(1):1-4
13. Xing Q, Qian X, Li H, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007;10(5):631-7
14. Arranz MJ, Li T, Munro J, et al. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998;8(6):481-4
15. Shen YC, Chen SF, Chen CH, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009;43(6):600-6
16. Hwang R, Shinkai T, De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacol 2005;181(1):179-87
17. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010;167(7):763-72
18. Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000;10(4):335-41
19. Schafer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001;158(5):802-4
20. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008;9(10):1437-43
21. Dahmen N, Muller MJ, Germeyer S, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Res 2001;49(1-2):223-5
22. Vijayan NN, Bhaskaran S, Koshy LV, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007;3:34
23. Lane HY, Lee CC, Chang YC, et al. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. International J Neuropsychopharmacol 2004;7(4):461-70
24. Jeanneteau F, Funalot B, Jankovic J, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci USA 2006;103(28):10753-8
25. Jonsson EG, Flyckt L, Burgert E, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatric genetics 2003;13(1):1-12 (Pubitemid 36293138)
26. Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010;10(3):200-18
27. Hwu HG, Hong CJ, Lee YL, et al. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998;44(6):483-7
28. Zhao AL, Zhao JP, Zhang YH, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005;115(11):1539-47
29. Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacol 1999;141(1):6-10
30. Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998;3(1):61-6
31. Parsons MJ, D'Souza UM, Arranz MJ, et al. The-1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004;56(6):406-10
32. Polesskaya OO, Aston C, Sokolov BP. Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1. J Neurosci Res 2006;83(3):362-73
33. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32(2):93-9
34. Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346(8970):281-2
35. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19(2):123-32
36. Lin CH, Tsai SJ, Yu YW, et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999;10(1):57-60
37. Lane HY, Chang YC, Chiu CC, et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002;159(9):1593-5
38. Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008;23(1):61-7
39. Chen SF, Shen YC, Chen CH. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology 2009;205(2):285-92
40. Ellingrod VL, Lund BC, Miller D, et al. 5-HT2A receptor promoter polymorphism,-1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology Bull 2003;37(2):109-12
41. Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(3):470-4
42. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the-1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40
43. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996;217(2-3):177-8
44. Malhotra AK, Goldman D, Ozaki N, et al. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996;153(8):1092-4
45. Ellingrod VL, Perry PJ, Lund BC, et al. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 2002;22(6):622-4
46. Sodhi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995;7(1):169-72
47. Yu YW, Tsai SJ, Lin CH, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999;10(6):1231-3
48. Lane HY, Lin CC, Huang CH, et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004;67(1):63-70
49. Masellis M, Basile VS, Meltzer HY, et al. Lack of association between the T-C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001;47(1):49-58
50. Serretti A, Calati R, Mandelli L, et al. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006;7(12):1659-69
51. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15(5):473-500
52. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000;355(9215):1615-16
53. Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007;414(1):1-4
54. Dolzan V, Serretti A, Mandelli L, et al. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1562-6
55. Illi A, Mattila KM, Kampman O, et al. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J Clin Psychopharmacol 2003;23(5):429-34
56. Bertolino A, Caforio G, Blasi G, et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007;95(1-3):253-5
57. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90(1-3):86-96
58. Barnett JH, Scoriels L, Munafo MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008;64(2):137-44 Available from: http://www.cypalleles.ki.se, as of July 20, 2010
59. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20(2):71-8
60. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. European archives of psychiatry and clinical neuroscience 2005;255(4):261-8
61. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6
62. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009;24(16):2309-15
63. Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007;12(9):794-5
64. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13(5):544-56
65. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996;93(5):1945-9
66. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27(1):105-19
67. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006;83(2-3):185-92
68. Tsai HT, North KE, West SL, et al. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010;153B(1):57-66
69. Tsai HT, Caroff SN, Miller del D, et al. A candidate gene study of tardive dyskinesia in the CATIE schizophreniatrial. Am J Med Genet B Neuropsychiatr Genet 2010;153B(1):336-40
70. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6(2):225-9
71. Tan EC, Chong SA, Mahendran R, et al. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001;50(2):144-7
72. Lattuada E, Cavallaro R, Serretti A, et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004;7(4):489-93
73. Lerer B, Segman RH, Tan EC, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005;8(3):411-25
74. Deshpande SN, Varma PG, Semwal P, et al. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr genet 2005;15(3):157-8
75. Wilffert B, Al Hadithy AF, Sing VJ, et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: curacao extrapyramidal syndromes study IX. J Psychopharmacology 2009;23(6):652-9
76. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacology Biol Psychiatry 2009;33(3):475-81
77. Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug metabolism and disposition: the biological fate of chemicals 1992;20(3):446-50
78. Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiol 2004;49(4):167-73
79. Fu Y, Fan CH, Deng HH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta pharmacologica Sinica 2006;27(3):328-32
80. Kobylecki CJ, Jakobsen KD, Hansen T, et al. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009;59(4):222-6
81. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005;15(3):151-8
82. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-9
83. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5¢-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125(4):803-8
84. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000;5(4):410-17
85. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005;5(1):60-9
86. Zai CC, Tiwari AK, Basile V, et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(1):50-6
87. Schillevoort I, de Boer A, van der Weide J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002;12(3):235-40
88. Inada T, Senoo H, Iijima Y, et al. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003;13(3):163-8
89. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66(1):15-27
90. Crescenti A, Mas S, Gasso P, et al. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008;35(7):807-11
91. Laika B, Leucht S, Heres S, et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J 2009;9(6):395-403
92. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol, Diabetes Obesity 2010;17(5):460-6
93. Muller DJ, Zai CC, Sicard M, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2010. [Epub ahead of print]
94. Lencz T, Robinson DG, Napolitano B, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. PharmacogenetGenomics 2010;20(9):569-72
95. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics 2010;20(6):359-66
96. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007;10(5):697-704
97. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010;175(3):271-3
98. Souza RP, De Luca V, Muscettola G, et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1848-53
99. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008;69(9):1416-22
100. Park YM, Chung YC, Lee SH, et al. G-protein beta3 Subunit Gene 825C/T Polymorphism is not associated with olanzapine-induced weight gain in Korean Schizophrenic patients. Psychiatry Investig 2009;6(1):39-43
101. Cichon S, Craddock N, Daly M, et al. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009;166(5):540-56
102. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2009. [Epub ahead of print]
103. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 2009;206(3):491-9
104. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2010. [Epub ahead of print]
105. Aberg K, Adkins DE, Bukszar J, et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010;67(3):279-82
106. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;14(11):1024-31
107. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009;14(8):804-19
108. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70(6):801-9
109. Schumacher J, Schulze TG, Wienker TF, et al. Pharmacogenetics of the clozapine response. Lancet 2000;356(9228):506-7
110. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 2006;10(3):135-51
111. Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005;25(5):427-34
112. Yamanouchi Y, Iwata N, Suzuki T, et al. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003;3(6):356-61
113. Suzuki A, Kondo T, Mihara K, et al. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur Arch Psychiatry Clin Neurosci 2001;251(2):57-9
114. Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005;15(2):143-51
115. Kwon JS, Kim E, Kang DH, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008;18(12):897-907
116. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97(6):714-19
117. Gaitonde EJ, Morris A, Sivagnanasundaram S, et al. Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genetics 1996;67(5):455-8
118. Ebstein RP, Macciardi F, Heresco-Levi U, et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47(1):6-16
119. Malhotra AK, Goldman D, Buchanan RW, et al. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol Psychiatry 1998;3(1):72-5
120. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999;10(1):17-20
121. Joober R, Toulouse A, Benkelfat C, et al. DRD3 and DAT1 genes in schizophrenia: an association study. J Psychiatr Res 2000;34(4-5):285-91
122. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 2002;162(1):18-23
123. Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004;124B(1):1-5
124. Lane HY, Hsu SK, Liu YC, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005;25(1):6-11
125. Cordeiro Q, Miguita K, Miracca E, et al. Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia. Sao Paulo Med J 2006;124(3):165-7
126. Xuan J, Zhao X, He G, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008;33(2):305-11
127. Barlas IO, Cetin M, Erdal ME, et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet 2009;150B(1):56-60
128. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993;341(8837):116
129. Rao PA, Pickar D, Gejman PV, et al. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994;51(11):912-17
130. Shaikh S, Collier DA, Sham P, et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Medl Genet 1995;60(6):541-5
131. Rietschel M, Naber D, Oberlander H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996;15(5):491-6
132. Kohn Y, Ebstein RP, Heresco-Levy U, et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. Eur Neuropsychopharmacol 1997;7(1):39-43
133. Kaiser R, Konneker M, Henneken M, et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000;5(4):418-24
134. Zalsman G, Frisch A, Lev-Ran S, et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003;13(3):183-5
135. Nothen MM, Rietschel M, Erdmann J, et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995;346(8979):908-9
136. Masellis M, Paterson AD, Badri F, et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995;346(8982):1108
137. Nimgaonkar VL, Zhang XR, Brar JS, et al. 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatric genetics 1996;6(1):23-7
138. Jonsson E, Nothen MM, Bunzel R, et al. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996;347(9018):1831
139. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999;24(2):141-6
140. Hamdani N, Bonniere M, Ades J, et al. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005;377(1):69-74
141. Rietschel M, Naber D, Fimmers R, et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997;8(8):1999-2003
142. Malhotra AK, Goldman D, Ozaki N, et al. Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport 1996;7(13):2100-2
143. Tsai SJ, Hong CJ, Yu YW, et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 2000;44(3):177-81
144. Illi A, Kampman O, Hanninen K, et al. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum Psychopharmacol 2007;22(4):211-15
145. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995;39(4):417-20
146. Aitchison KJ, Munro J, Wright P, et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 1999;48(3):388-94
147. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72(4):438-52
148. Kohlrausch FB, Gama CS, Lobato MI, et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics 2008;18(7):599-609
149. Chen CH, Wei FC, Koong FJ, et al. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41(7):827-9
150. Hori H, Ohmori O, Shinkai T, et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001;105(8):774-8
151. Segman RH, Goltser T, Heresco-Levy U, et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003;3(5):277-83
152. Chong SA, Tan EC, Tan CH, et al. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;116B(1):51-4
153. Liou YJ, Lai IC, Liao DL, et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 2006;86(1-3):323-5
154. Zai CC, Hwang RW, De Luca V, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007;10(5):639-51
155. Inada T, Arinami T, Yagi G. Association between a polymorphism in the promoter region of the dopamine D2 receptor gene and schizophrenia in Japanese subjects: replication and evaluation for antipsychotic-related features. Int J Neuropsychopharmacol 1999;2(3):181-6
156. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25(5):448-56
157. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2(2):139-45
158. Inada T, Dobashi I, Sugita T, et al. Search for a susceptibility locus to tardive dyskinesia. Hum Psychopharmacol Clin Exp 1997;12(1):35-9
159. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999;21(1):17-27
160. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4(3):247-53
161. Lovlie R, Daly AK, Blennerhassett R, et al. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International J Neuropsychopharmacol 2000;3(1):61-5
162. Rietschel M, Krauss H, Muller DJ, et al. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000;250(1):31-5
163. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44(2):95-8
164. Garcia-Barcelo MM, Lam LC, Ungvari GS, et al. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001;108(6):671-7
165. Mihara K, Kondo T, Higuchi H, et al. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002;114(6):693-5
166. Woo SI, Kim JW, Rha E, et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002;56(4):469-74
167. Zhang ZJ, Zhang XB, Hou G, et al. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet 2003;13(3):187-92
168. Liou YJ, Liao DL, Chen JY, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromol Med 2004;5(3):243-51
169. Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16(2):111-17
170. Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009;19(5):317-28
171. Basile VS, Ozdemir V, Masellis M, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Molecular psychiatry 2001;6(2):230-4
172. Herken H, Erdal ME, Boke O, et al. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003;18(2):77-81
173. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 2000;152(4):408-13
174. Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 2002;7(2):137-9
175. Matsumoto C, Shinkai T, Hori H, et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004;127(1-2):1-7
176. Han DH, Lee JH, Lee YS, et al. The association between tardive dyskinesia induced by haloperidol and polymorphisms in the serotonin transporter gene and catecholamine-O-methyltransferase gene in Korean schizophrenic patients. Clin Psychopharmacol Neurosci 2005;3:16-21
177. Lai IC, Wang YC, Lin CC, et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005;112(8):1107-13
178. Kang SG, Choi JE, Park YM, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57(1-2):22-5
179. Nikoloff D, Shim JC, Fairchild M, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002;2(6):400-7
180. Lohmann PL, Bagli M, Krauss H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003;36(2):73-8
181. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005;75(1):21-6
182. Matsumoto C, Ohmori O, Shinkai T, et al. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004;14(4):209-13
183. Chong SA, Tan EC, Tan CH, et al. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003;28(3):185-9
184. Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001;105(6):498-501
185. Spina E, Ancione M, Di Rosa AE, et al. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 1992;42(3):347-8
186. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000;56(9-10):679-83
187. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002;359(9323):2086-7
188. Tsai SJ, Hong CJ, Yu YW, et al.-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360(9347):1790
189. Basile VS, Masellis M, De Luca V, et al. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002;360(9347):1790-1
190. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160(4):677-9
191. Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005;133B(1):97-100
192. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the-759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005;134B(1):76-8
193. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15(4):195-200
194. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr genet 2005;15(4):285-9
195. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26(2):128-34
196. Ryu S, Cho EY, Park T, et al.-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacology Biol Psychiatry 2007;31(3):673-7
197. Park YM, Cho JH, Kang SG, et al. Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008;33(1):55-60
198. Kuzman MR, Medved V, Bozina N, et al. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008;160(3):308-15
199. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009;9(4):234-41
200. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009;29(1):65-8
201. Opgen-Rhein C, Brandl EJ, Muller DJ, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010;11(6):773-80
202. Tsai SJ, Yu YW, Lin CH, et al. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004;50(1):37-40
203. Wang YC, Bai YM, Chen JY, et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005;15(10):743-8
204. Bishop JR, Ellingrod VL, Moline J, et al. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006;12(2):BR47-50